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Parkinson's diseaseProtein homeostasis, or proteostasis, is the process ofmaintaining the conformational and functional integrity of the
proteome. The failure of proteostasis can result in the accumulation of non-native proteins leading to their aggrega-
tion and deposition in cells and in tissues. The amyloid ﬁbrillar aggregation of the protein α-synuclein into Lewy
bodies and Lewy neuritis is associatedwith neurodegenerative diseases classiﬁed asα-synucleinopathies, which in-
clude Parkinson's disease and dementia with Lewy bodies. The small heat-shock proteins (sHsps) are molecular
chaperones that are one of the cell's ﬁrst lines of defence against protein aggregation. They act to stabilise partially
folded protein intermediates, in an ATP-independent manner, to maintain cellular proteostasis under stress condi-
tions. Thus, the sHsps appear ideally suited to protect againstα-synuclein aggregation, yet these fail to do so in the
context of theα-synucleinopathies. This review discusses how sHsps interactwithα-synuclein to prevent its aggre-
gation and, in doing so, highlights themulti-faceted nature of themechanisms used by sHsps to prevent the ﬁbrillar
aggregation of proteins. It also examines what factorsmay contribute toα-synuclein escaping the sHsp chaperones
in the context of the α-synucleinopathies.
Crown Copyright © 2014 Published by Elsevier B.V. All rights reserved.1. Introduction
Protein homeostasis (proteostasis) is themaintenance of proteins at
appropriate levels and in the correct (functional) conformation [1].
Proteostasis involves a complex network of integrated systems, includ-
ing molecular chaperone proteins, which ensures the conformational
(and hence functional) integrity of synthesised proteins and the degrada-
tion of proteinswhich are no longer functional.When proteostasismech-
anisms falter, proteins can misfold, aggregate and accumulate, often
resulting in disease [2]. One example of this is the α-synucleinopathies,
a group of neurodegenerative diseases that include Parkinson's disease
(PD), multiple system atrophy and dementia with Lewy bodies [3], in
which the proteinα-synuclein (α-syn) aggregates into insoluble amyloid
ﬁbrils and forms deposits (termed Lewy bodies and Lewy neurites) inside
cells.Whilst the aetiology of theα-synucleinopathies ismulti-faceted, this
review will focus speciﬁcally on the links of these diseases with thein; apoC-II, apolipoprotein C-II;
, amyotrophic lateral sclerosis;
n; Hsp, heat-shock protein; PD,
small heat-shock protein; TEM,
al Research Institute, University
22, Australia. Tel.:+61 2 42 213
r B.V. All rights reserved.ﬁbrillar aggregation of α-syn (for a more comprehensive review of the
pathology and genetics of the α-synucleinopathies, see [4–8]).
Heat-shock proteins (Hsps) are a broad family of molecular chaper-
ones that play important roles in proteostasis. They function under nor-
mal physiological conditions and when cells are under stress, e.g. when
they are exposed to elevated temperatures or reactive oxygen species
(ROS) [9]. One of themost up-regulated classes of Hsps induced by stress
is the small heat-shock proteins (sHsps) which have been implicated as
important components of the cellular response to the onset of many pro-
tein aggregation disorders, including the α-synucleinopathies.
The sHsps act as the cell's ﬁrst line of defence against protein aggrega-
tion. Their ability to prevent protein aggregation in vitro has been well
characterised using a variety of pathogenic and non-pathogenic proteins
[10–13], including α-syn [11,14,15]. Yet since the α-synucleinopathies
occur, it is evident that there are some circumstances whereby sHsps
(and other classes of molecular chaperones) fail to prevent the aggrega-
tion of α-syn in vivo. This review outlines the role of sHsps in cellular
proteostasis, with a particular focus on αB-crystallin (HSPB5, αB-c) and
Hsp27 (HSPB1), as these have been the most studied sHsps, including in
the context of the α-synucleinopathies (for recent reviews that focus on
the association and impact of other major chaperone classes, e.g. Hsp70
and Hsp90, on theα-synucleinopathies see [16–19]). In doing so, this re-
view provides insight into how these sHsps normally interact withα-syn
to prevent its toxic ﬁbrillar aggregation, andwhat factorsmay account for
the chaperone activity of sHsps being ineffective and/or overwhelmed in
the α-synucleinopathies.
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Proteostasis operates both inside and outside the cell (for recent
comprehensive reviews see [20,21]) and is dependent on numerous in-
tegrated pathways that control the lifecycle and fate of a protein (Fig. 1).
These pathways include those involved in gene transcription, mRNA
translation and protein synthesis on the ribosome, through to protein
trafﬁcking and compartmentalisation in cellular organelles, and ﬁnally
to protein degradation by the proteasome [22]. As such, the macromo-
lecular elements comprising the cellular proteostasis network include
transcription factors, RNA processing and translocation factors, folding
enzymes, trafﬁcking components, molecular chaperones and degrada-
tion components. The capacity to maintain proteostasis varies between
cell types [23], and is thought to be reﬂective of the composition and
concentration of components of the network that arise as a result of dif-
ferences during cellular differentiation and development [24]. Whilst
this capacity is ﬁnite at any point in time, it can be spatially and tempo-
rally altered through varying the amount and/or activity of individual
components. Thus, an appropriate analogy for proteostasis is a see-
saw; there is an intricate balance required in the use of energy and re-
sources to maintain the functional integrity of the proteome and thus
avoid protein aggregation and disease.
2.1. Molecular chaperones
The biological function of (most globular) proteins is inextricably
linked to them obtaining the correct (native) fold [25]. However,
many proteins are intrinsically disordered and do not fold; instead
they remain unfolded with some acquiring structure once they bind to
other proteins or membranes [26–28]. Unfolding is important in the
life cycle of many proteins; it is required in various biological processes
including protein trafﬁcking, secretion and translocation across mem-
branes, as well as regulation of the cell cycle [29]. In all cases, attainingFig. 1. Cellular proteostasismechanisms. In the endoplasmic reticulum (ER), molecular chape
for transport into the cytosol. Persistent or misfolded protein intermediates can be proteolytica
intermediates are recognised bymolecular chaperones and targeted for refolding or degradation
intermediates, insoluble aggregates can accumulate within the ER or cytosol as aggresomes. Adthe correct native state, whether folded or disordered, is essential for
protein function and often relies on the presence of molecular chaper-
ones. Molecular chaperones protect and stabilise non-native regions of
proteins, or assist in proteins acquiring their native state, without con-
tributing conformational information or forming part of the ﬁnal native
structure [32,33]. Chaperones achieve this by interacting with (and
stabilising) partially folded and unfolded protein intermediates in
order to prevent improper associations that could otherwise lead to
misfolding and aggregation [34]. In addition, chaperones can also facili-
tate the folding of multi-domain proteins, through transient sequestra-
tion of the folding intermediates [24].
Due to their role in assisting proteins to acquire and maintain their
native conformation, molecular chaperones are key components of the
proteostasis network. They participate in protein folding, complex as-
sembly, protein trafﬁcking, protein stabilisation and protein degrada-
tion. As their name implies, Hsps are molecular chaperones that are
most commonly expressed as part of the cellular response to stress, al-
though somemembers are constitutively expressed and play important
roles under non-stress conditions [35]. The Hsps have been classiﬁed
into groups based on the mass of their monomeric subunits. They in-
clude Hsp100, Hsp90, Hsp70, Hsp60 and the sHsps [36]. Chaperones
can also be generally classiﬁed as having either a ‘foldase’ or ‘holdase’
type action. For example, Hsp70 and Hsp60 are classiﬁed as ‘foldase’
type chaperones as they actively facilitate the folding of protein inter-
mediates to their native folded state. In doing so, they often act in tan-
dem, with Hsp70 acting ﬁrst on the polypeptide chain upon its exit
from the ribosome. Their mechanism of action is dependent on ATP hy-
drolysis, which results in cycles of high- to low-afﬁnity target protein
binding, which promotes folding of the target protein [37,38]. Foldase
chaperones also encompass the so-called ‘unfoldase’ action attributed
to some chaperones, including Hsp70, in which ATP hydrolysis is used
to unfold or disaggregate misfolded or aggregated proteins to provide
folding-competent intermediates [39,40]. In contrast, so-called ‘holdase’rones assist newly synthesised protein intermediates to fold into their native conformation
lly degraded within the ER or transported to the cytosol [30]. Once in the cytosol, protein
via lysosomal or proteasomal pathways [31].When thesemechanisms fail to clear protein
apted from [22].
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intermediate states of proteins to stabilise them and prevent their mu-
tual association. The mechanism of action of holdase chaperones is
ATP-independent since they do not have an active role in folding pro-
teins and their association with target proteins is driven primarily
through hydrophobic interactions. However, the ability of holdases to
function in the ATP-depleted environment that occurs in the cell
when it is under stress ensures their function is not compromised at
the time cell viability is threatened.When energy levels permit, holdase
chaperones can deliver target proteins to foldases for refolding, or to the
cellular protein degradation systems such as the proteasome [37,38,41].
2.1.1. The role of molecular chaperones in protein degradation
When a protein can no longermaintain its correct conformation, the
cell utilises degradation pathways such as the ubiquitin–proteasome
machinery and autophagic–lysosomal trafﬁcking systems to remove it.
Misfolded proteins are recognised by the ubiquitin–proteasome system,
which labels and degrades them through a highly regulated pathway.
Using a series of ubiquitin ligase enzymes, ubiquitin polypeptide chains
are covalently linked tomisfolded proteins, marking them as substrates
for selective degradation within the proteasome [42,43]. Lysosomal
mechanisms, such as macroautophagy and microautophagy, are
less selective; membrane-bound vesicles capture a selection of the
cytosol, which is then targeted for degradation. By contrast, chaperone-
mediated autophagy provides a level of targeted degradation as it relies
on the recognition of a target motif in cytosolic proteins by speciﬁc chap-
erones, which then deliver the proteins to themembrane of the lysosome
for internalisation anddegradation [44]. The sHspsmayplay a role in all of
these degradation pathways; for instance,αB-c stimulates ubiquitination
of insoluble proteins which marks them for ubiquitin-dependent
degradation [45], Hsp22 (HspB8), in cooperation with Bag3, pro-
motes degradation of mutant Huntington protein through induction
of macroautophagy [46] and Hsp27 targets misfolded cystic ﬁbrosis
transmembrane conductance regulator proteins for degradation in
the proteasome [47]. Whether these activities are speciﬁc to individ-
ual sHsps or represent more generic traits of sHsp family members is
yet to be determined, however it is clear from this work that as a
chaperone class, sHsps function not only to bind to proteins to pre-
vent their aggregation but can also facilitate their degradation when
misfolded [48].
2.2. When proteostasis fails
Anumber of factors can inﬂuence the ability of a cell, tissue or organ-
ism to maintain proteostasis. Changes in cellular ATP levels, amino acid
pools, metabolites, lipid homeostasis and ion balance can all disrupt the
protein folding and degradation capabilities of the cell [24]. Signalling
pathways can be exploited to control transcriptional, translational and
post-translational mechanisms in the cell in order to regulate protein
synthesis, folding, trafﬁcking and degradation [24]. However, disruption
of any element within this integrated network can result in proteostasis
dysfunction. Aberrant protein folding and protein aggregation are now
recognised as key factors in many diseases, collectively termed protein
misfolding or conformational diseases [49]. These diseases, which
include type II diabetes, cataract and neurological disorders such as
Alzheimer's disease and PD [50], are associated with the aggregation
and precipitation of misfolded protein into either amorphous or ﬁbrillar
aggregates. Their prevalence – and the prediction that this will increase
dramatically over the next few decades as a consequence of the ageing
population inmany countries [51] – underlies the importance of under-
standing the network of pathways that maintain proteostasis.
3. Parkinson's disease is an aggregation disorder
PD is the second most prevalent neurological disorder, with its
world-wide incidence projected to reach at least 8.7 million individualsover 50 years of age by 2030 [51–53]. PD is characterised by motor
manifestations including tremor, rigidity, bradykinesia and postural in-
stability, which can also be accompanied by non-motor symptoms such
as sleep impairment, neuropsychiatric disorders and olfactory deﬁcits
[54,55]. All of these symptoms are linked to a gradual reduction in
dopamine content associated with the progressive loss of dopaminergic
neurons in the substantia nigra pars compacta, a region located in the
midbrain.
The histological hallmark of PD is the presence of protein inclusions,
known as Lewy bodies or Lewy neurites, localised to the cell body or cell
processes respectively [56]. These distinctive spherical protein inclu-
sions are found in the cytoplasm of nigral neurons and are characterised
by a dense protein core surrounded by a halo of ﬁbrils and auxiliary
proteins [57]. The principal protein contained within these inclusions
is α-syn [58]. The α-syn-rich proteinaceous deposits are not only
found in PD but are also detected in other neurological disorders includ-
ing dementia with Lewy bodies, some forms of Alzheimer's disease and
multiple system atrophy [59–61].
Since α-syn is expressed in cell types other than neurons, often at
higher levels (e.g. red blood cells [62,63]), the question arises: why are
neurons so susceptible to forming α-syn inclusions? Neurons are
thought to be particularly vulnerable to these protein accumulations
as they are post-mitotic and therefore unable to dilute potentially
toxic species through cell division [64]. Moreover, expression of some
molecular chaperones, including the sHsps, appears to be lower in do-
paminergic neurons compared to other cell types which may compro-
mise their ability to prevent protein aggregation [23].
3.1. α-Synuclein in Parkinson's disease
α-Synuclein, a 140 amino acid protein, was initially identiﬁed as a
neuron-speciﬁc protein localised within the nucleus and presynaptic
terminals [65]. From a functional perspective, there is still no deﬁnitive
evidence for the roleα-syn plays in cells. It has been implicated inmod-
ulating synaptic activity throughmembrane processes, includingneuro-
transmitter release, trafﬁcking and biogenesis [66,67]. In addition to the
full-length formof the protein, there are two shorter isoformswhich are
126 and 112 amino acids in length and result from in-frame deletions of
exon 3 and 5 respectively [68,69]. However the full length isoform is by
far the most abundant in the brain [70]. Truncated versions, derived
from proteolytic cleavage, have been identiﬁed as signiﬁcant com-
ponents of Lewy body inclusions [60,70,71]. Truncation fragments
of α-syn also have a higher aggregation propensity than the full
length form, both in vitro and in vivo [72–75].
As well as the association ofα-syn with Lewy body pathology, there
is a strong genetic association of α-syn with PD [76] which has further
piqued interest into the role of this protein in disease. PD may be either
early onset (before) or late onset (after 40 years of age). Althoughmost
commonly presenting as a late onset, sporadic disease of unknown
aetiology, a familial formwith an autosomal dominant pattern of inher-
itance among early onset patients was initially identiﬁed in two small
kindred [77,78]. This led to the identiﬁcation of three missense muta-
tions in the α-syn gene which correlate to early-onset and aggressive
PD: A53T, A30P and E46K [76,79,80]. Multiplication of the α-syn gene
has also been associated with the development of α-syn inclusions
[60,71]. Gene copy number is strongly correlatedwith the age of disease
onset; duplication results in an average age of onset of 48.4 years, whilst
triplication results in an average age of onset of 33.4 years [81].
3.1.1. α-Synuclein aggregation
Due to the presence of large amounts of aggregated α-syn in Lewy
bodies and Lewy neurites, and the correlation between α-syn genetic
abnormalities and early onset PD, the mechanism and kinetics by
whichα-syn aggregates to form amyloidﬁbrils in vitro have been exam-
ined in detail (Fig. 2). It has been generally accepted thatα-syn exists as
an unstructured monomeric protein in its native state in solution.
Fig. 2. Amyloid ﬁbrillar aggregation of α-syn. Unfolded α-syn exists as a monomer that can interact with lipids, to form an α-helical structure [85]. There is some evidence that a tet-
rameric α-helical form of α-syn also exists in cells [84] and monomeric unfolded forms of α-syn may be in equilibrium with this tetramer. Unfolded α-syn aggregates through a
nucleation-dependentmechanism, inwhich aggregation-proneα-synmonomers associate to form soluble preﬁbrillar oligomeric nuclei. This is followed by the elongation of these nuclei
intomature amyloidﬁbrils. Fibrillar aggregatesmay thenbe sequestered into Lewy body or Lewy neurites. Alternatively, fragmentation ofmatureﬁbrils can generate additional oligomeric
nuclei which seed secondary aggregation events.
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lipids it attains anα-helical structure and recent evidence has suggested
it may form a tetramer in some cell types [82–86]. Within inclusions,
α-syn is assembled into highly-ordered, β-sheet rich amyloid ﬁbrils.
Similarly, under conditions of physiological pH and temperature in vitro,
puriﬁedα-syn assembles intoﬁbrils resembling those found in diseased
brains [87–89]. Amyloid ﬁbril formation occurs via a nucleation-
dependent mechanism in which the formation of oligomeric nuclei is
the rate limiting step, which is followed by rapid elongation and assem-
bly into mature ﬁbrils [90–92]. All three α-syn mutations associated
with PD have been found to inﬂuence the early stages of aggregation,
either nuclei formation or ﬁbril growth, when their aggregation pro-
pensities have been assessed in vitro [93]. Each α-syn mutant exhibits
distinct ﬁbrillation kinetics and/or aggregate morphologies: A53T and
E46K α-syn form ﬁbrils more rapidly than the wild-type (WT) protein,
and A30P α-syn forms mature ﬁbrils more slowly, although smaller
oligomeric species are formed more rapidly by this mutant [15,94,95].
The difference in ﬁbrillation kinetics is generally attributed to variations
in the rate of nucleation, as opposed to the rate of elongation [96,97]. As
with genemultiplication, the aggregation propensity of eachα-syn var-
iant correlates well with disease onset and the severity of familial PD,
with the A53T variant aggregating the fastest and being associated
with the earliest and most aggressive disease phenotype [98].
In addition to the inherent aggregation propensity of α-syn, a num-
ber of factors have been shown to inﬂuence the rate at which the protein
forms ﬁbrils. For example, aggregation is promoted by the presence of
metals, pesticides, lipids, membranes, and under conditions of low pH
or molecular crowding [99–101]. In general, these factors increase the
concentration of the preﬁbrillar intermediates crucial for the formation
of nuclei during the rate-limiting step [57,99–101]. Conversely, aggrega-
tion is hindered by the presence of the related by non-aggregating pro-
teins β- and γ-synuclein [102,103], as well as molecular chaperones
such as sHsps [15,104]. Changes in the rate at which aggregation occurs
(e.g. through the inﬂuence of the above mentioned factors), may there-
fore contribute to the failure of proteostasis elements to prevent α-syn
aggregation in a disease context.
3.1.2. α-Synuclein pathogenicity
Although the exact physiological function of α-syn is yet to be de-
ﬁned, based on knowledge of its broad physiological role of modulating
synaptic activity, some features of PDmay be ascribed to toxicity associ-
atedwith loss of function encounteredwhenα-syn in the cell is seques-
tered and deposited following aggregation. The reduced availability of
α-syn would impact on its ability to interact with cellular membranes
[105]. Failure of α-syn to complete its physiological role within the
cell could potentially cause neuronal damage, particularly in thesynaptic terminal [106]. However, it is considered unlikely that this is
the primary pathological effect ofα-syn aggregation sinceα-syn knock-
out mice do not display any overt neuropathological or behavioural
phenotypes, in contrast to mice that overexpress α-syn [107,108]. In-
stead, it is now generally accepted that the accumulation of α-syn into
Lewy bodies and Lewy neurites leads to disease due to a toxic gain-of-
function inherent in the proteinwhen it exceeds a threshold concentra-
tion and adopts a ﬁbrillar-type conformation [106]. The aggregation of
α-syn, exacerbated by a decrease in the ability of the cell to dispose of
damaged proteins, results in the accumulation of non-functional (po-
tentially toxic) α-syn species, which may interfere with normal met-
abolic processes.
3.1.3. The debate surrounding the identity of the cytotoxic α-synuclein
species
For some time, the toxic α-syn species responsible for neurodegen-
eration has been hotly debated. Initially, cytoplasmic inclusions were
thought to be a characteristic feature of dead or dying neurons, with
the deposition of mature amyloid ﬁbrils into Lewy bodies identiﬁed as
the neurotoxic event. This was primarily based on ﬁndings suggesting
that inclusions may suppress organelle function, interfere with axonal
transport, or induce energy failure via hyperubiquitination [109,110].
However, Lewy bodies are commonly found in living neurons, and are
also present in up to 15% of healthy, aged individuals [111,112].
In cell-based models and in vivo, neurotoxicity correlates best with
the appearance of soluble α-syn oligomers as opposed to inclusions
[113]. Toxicity is usually observed in the absence ofmatureα-syn ﬁbrils
or detectable deposition into inclusions in cell models [113,114]. More-
over, surviving dopaminergic neurons demonstrate equivalent viability
irrespective of the presence or absence of Lewy bodies [115]. Further-
more, transgenicmice exhibit neurodegeneration outside the substantia
nigra in the absence of ﬁbrillary inclusions, and α-syn ﬁbril-containing
inclusions in Drosophila are observed in the absence of neurodegenera-
tion [116–118].
A recent study utilised a rat lentivirus system to examine the cellular
toxicity of E35K and E37K α-syn, which were speciﬁcally designed to
form small oligomers, compared to anα-syn variant encompassing res-
idues 30–110, which forms ﬁbrils [119]. Following injection into the
substantia nigra, cell loss was assessed based on a reduction in tyrosine
hydroxylase-positive neurons in this region. Higher toxicity was ob-
served in dopaminergic neurons of animals exposed to oligomer-
forming variants of α-syn compared to those which formed ﬁbrils
[119]. Finally, dopamine and its metabolites inhibit the conversion of
protoﬁbrils to mature amyloid both in vitro and in vivo [120–122], pro-
viding a potential rationalisation for the vulnerability of dopaminergic
neurons since they would therefore promote protoﬁbril formation.
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tiated by α-syn, thereby promoting apoptosis [114].
In light of this evidence, the predominant consensus is now that sol-
uble preﬁbrillar oligomeric species of α-syn are the most toxic entity,
and ﬁbrils are the less toxic end-product of the aggregation process
[123,124]. Yet, mature ﬁbrils can be a source of cytotoxic oligomeric
species due to their fragmentation [125]. Thus, it has been proposed
that the formation of protein inclusions may represent an additional
protectivemechanism employedby the cell [61,123,126]. The formation
of inclusion bodies within cells may therefore represent a protection
strategy used by the cell to sequester toxic oligomeric forms that may
arise due to ﬁbril fragmentation. In this way, potentially toxic species
can be isolated in speciﬁc compartments in the cell to protect it from
their harmful effects [127].
The generic toxicity of preﬁbrillar (i.e. small soluble oligomeric)
species is also evident in non-disease-associated proteins capable of
forming amyloid. For example, using two unrelated and non-disease-
associated protein domains, the SH3 domain from bovine phosphatidyl-
inositol-3'-kinase and the amino terminal of HypF from E. coli, Bucciantini
and colleagues [128] demonstrated that oligomeric forms of these pro-
teins generated during the early stages of aggregation were inherently
cytotoxic when added to cells in culture. As well, early preﬁbrillar
aggregates of apomyoglobin are toxic to cultured ﬁbroblasts via
their ability to alter membrane permeability [129]. Finally, soluble
amyloidogenic oligomers of equine lysozyme are toxic to both primary
and cultured neuronal cells; cytotoxicity is correlated with the size of
the oligomerswithin the samplewith larger species being less cytotoxic
[130]. Thus, it is concluded that preﬁbrillar aggregates are the most
toxic entity formed during amyloid ﬁbril formation.
The toxicity of aggregates formed from a variety of pathogenic and
non-pathogenic proteins correlateswith the level of exposedhydropho-
bicity at the aggregate surface [131]. Initially, there is an abundance of
soluble oligomeric aggregates with a high surface-to-volume ratio and
a high degree of exposed hydrophobicity [132]. As the aggregate in-
creases in size over time, there is a decrease in the surface-to-volume
ratio and amount of exposed hydrophobicity [131–133]. The higher
proportion of hydrophobic residues exposed on the smaller oligomeric
species enables them to participate in inappropriate interactions that
can ultimately lead to cell death [49]. It is important to note, however,
that although this mechanism appears generally applicable to patho-
genic and non-pathogenic proteins alike, ultimately the amino acid se-
quence deﬁnes the kinetics by which a protein aggregates and the
speciﬁc properties of any aggregate formed. Thus, the speciﬁc toxicity
of a protein is inﬂuenced by its relative ability to form oligomers, the
rate these oligomers are then converted tomatureﬁbrils and the amount
of hydrophobicity exposed throughout this process [131].
The relative hydrophobicity of preﬁbrillar aggregates appears to
endow them with a large potential to cause cellular damage. Many
mechanisms have been proposed for α-syn toxicity (summarised in
Fig. 3). When considering the mechanism of toxicity of these species,
it is important to also take into account their physical properties. For ex-
ample, α-syn is capable of lipid-binding [134,135] and the oligomers
formed from α-syn can be small, ﬂexible spheroids, characteristics
which favour their association with membranes and pore formation
[136]. Pore formation may occur on any of the cellular membranes,
both inter- and intra-cellular, providing several targets for α-syn medi-
ated toxicity [137]. For instance, pore formation within the plasma
membranemay allow the abnormal ﬂow of ions causing cellular dys-
function and leading to apoptosis [134,138]. This is indirectly sup-
ported by work showing that cells expressing α-syn have increased
cation permeability [139]. Through interactionwith lysosomal mem-
branes, α-syn aggregates may inhibit chaperone-mediated autopha-
gy, leading to an accumulation of substrates and proteasome inhibition
[140]. Alternatively, preﬁbrillar oligomers can impair axonal transport
via hyperphosphorylation of Tau, a protein normally responsible for
stabilising and regulating the microtubule assembly and interactingwith membranous cargo [141]. By disrupting transport from the endo-
plasmic reticulum (ER) to Golgi, α-syn can cause ER stress and Golgi
fragmentation [113,140]. Energy production can also be impaired due
to effects of oligomeric α-syn on mitochondria [142]. In addition,
α-syn is implicated in reducing dopamine release and its subsequent
reuptake in the synaptic terminal [143]. The active secretion or pas-
sive release (following death) of aggregated forms of α-syn can also
result in cell-to-cell transfer of toxic intermediates that alter synap-
tic protein expression and excitability [146]. Moreover, these extra-
cellular species of α-syn can activate surrounding astrocytes and
glia, resulting in the production of ROS and proinﬂammatory cyto-
kines, which in turn can be toxic to surrounding neurons [145]. Final-
ly, although inclusion bodies may sequester potentially harmful
aggregation intermediates, this process may also result in the deple-
tion of proteins that become associated with the inclusions from the
cytoplasm, leading to a loss in their biological activity [142]. Togeth-
er, these factors may lead to compromised cell viability (and cell
death). However, any one of these events (or combination thereof)
may be sufﬁcient given the delicate balance required to maintain
proteostasis.
3.2. Lewy bodies and Lewy neurites: α-synuclein is not alone
Whilst α-syn is the main constituent of Lewy bodies and Lewy
neurites, it is not the only protein found in these insoluble inclusions:
a range of other proteins have been identiﬁed including synuclein-
binding proteins, protein kinases, proteins implicated in the ubiquitin-
proteasome system and proteins associated with the cellular stress
response (e.g. molecular chaperones) [56]. Immunostaining of post-
mortem brain tissue from PD patients indicates that Hsp90, Hsp70,
Hsp40 and the sHsps are associated with Lewy bodies and Lewy
neurites [118,147,148]. With regard to the sHsps, diffuse Hsp27 was
identiﬁed throughout Lewy bodies and Lewy neurites in the substantia
nigra [147,149] and αB-c also colocalises with α-syn in Lewy bodies
and Lewy neurites [149–152]. In addition, post-translationally modiﬁed
forms of αB-c are a major component of oligodendral cytoplasmic
inclusions isolated from clinically conﬁrmed cases of multiple system
atrophy [59]. It remains to be establishedwhether these chaperones as-
sociatewith these protein inclusions before or after they form in the cell.
In any case, it appears that although these chaperone proteins are avail-
able to inhibit α-syn aggregation in cells, under certain circumstances
they are unable to prevent its deposition and instead become part of
the inclusions that are the hallmarks of the α-synucleinopathies.
4. Small heat-shock proteins as molecular chaperones
There are ten human sHsps (HSPB1–HSPB10) and of these the most
well characterised are Hsp27, αA-crystallin (HSPB4, αA-c), αB-c and
Hsp20 (HSPB6) [153,154]. Whilst sHsps are often described as ‘holdase’
chaperones, this term does not fully describe their chaperone activi-
ty [155] and not all sHsps have been shown to be capable of suppressing
target protein aggregation (e.g. HSPB9 and HSPB10). Structural aspects
of sHsps have been considered in detail elsewhere [156–159] and there-
fore the salient features are only summarised here. The sHsps are deﬁned
by their relatively small (compared to other Hsps) monomeric masses
(12–43 kDa), and the presence of a conserved central region referred to
as the α-crystallin domain. The α-crystallin domain is ~90 residues in
length and contains up to nine anti-parallel β-strands organised into β-
sheets in an immunoglobulin-like fold [160,161]. It is ﬂanked by N- and
C-terminal regions of variable length and sequence that predominantly
lack structure [162]. In mammalian sHsps, the extreme C-terminus is a
short, mobile and ﬂexible extension which is typically polar in nature
and contributes to stabilisation of the protein (and complexes it forms
with target proteins) during chaperone action [163,164]. The N-
terminal region contains regions of signiﬁcant hydrophobicity and has
been suggested to mediate the interaction between the chaperone and
Fig. 3. A schematic model for the potential mechanisms by which α-syn aggregation is toxic to neuronal cells. Aggregation-prone monomericα-syn associates to form soluble olig-
omeric nuclei leading to the formation of mature ﬁbrils. (1) Inclusion body formation: Fibrillar α-syn is sequestered into protein inclusions, which also contain various other cellular
proteins, including sHsps, potentially depleting the cell of these essential components (2) Initiation of the heat-shock response: An accumulation of toxic α-syn species within the
cell activates the heat-shock response pathway, initiating changes in transcription of stress response genes. (3) Blocking protein trafﬁcking from the ER to Golgi: Aggregation of
toxic forms ofα-syn in the cell can block protein transport from the ER to Golgi, inducing Golgi fragmentation. (4) Oxidative stress: Aggregation ofα-syn induces dopamine (DA)-dependent
ROS production, resulting in oxidative stress. (5) Defects in axonal transport: Aggregated α-syn induces hyperphosphorylation of tau in the axon, which causes defects in axonal transport
through restricting the ability of tau to modulate microtubule assembly. This impairs essential cellular transport as well as resulting in the accumulation of aggregated material in the cell
body. (6) Altered synaptic terminal excitability and protein expression: The presence of aggregatedα-syn in the synaptic compartment alters the distribution of synaptic terminal proteins,
diminishing synaptic vesicle release and leading to changes in synaptic terminal protein expression and excitability. (7) Impaired autophagy:Binding ofα-syn to lysosomalmembranes impairs
chaperone-mediated autophagic function, resulting in substrate accumulation and proteasomal impairment in the cell body. (8) Release of toxic α-syn species into extracellular space: Ag-
gregatedα-synmay be actively secreted (e.g. via exosomes) or passively released by dying neurons andbe subsequently taken up byneighbouring neurons, resulting in seeded aggregation and
altered synaptic terminal activity. Uptake by surrounding glia can induce proinﬂammatory activity including ROS production, which is toxic to surrounding neurons. (9) Impaired energy
production and increased ROS production: Localisation of α-syn to mitochondrial membranes may impair energy production or increase ROS formation. (10) Membrane pore formation:
Ring-like oligomeric α-syn species may inﬁltrate cellular membranes forming pores within the membrane and altering ion permeability. Figure compiled using information from
[113,114,134,138,140–145].
1835D. Cox et al. / Biochimica et Biophysica Acta 1842 (2014) 1830–1843its target protein [165–168], although recent work demonstrates that the
N-terminal region is not essential for chaperone function [169–171]. The
formation of oligomeric assemblies is another deﬁning feature of the
sHsps. Whilst in some species sHsps form well-deﬁned homogenous
multimers (e.g. wheat Hsp16.9), many mammalian sHsps members
(e.g. Hsp27,αB-c andαA-c) form large polydisperse oligomerswhich un-
dergo rapid subunit exchange [169,172–178]. The popular model of sHsp
chaperone action is that dissociated species (predominantly depicted as
dimers) are the most chaperone-active form; the rationale being that
these species have a higher degree of exposed hydrophobicity compared
to the larger oligomeric forms, thereby facilitating their interaction with
partially folded target proteins that expose signiﬁcant hydrophobicity to
solution [173,179]. In this model, the rate of subunit exchange of sHsps,
which is highly dependent on solution conditions (e.g. temperature) but
independent of sHsp concentration [178,180], dictates how fast chaper-
one active subunits can be liberated from large oligomers in order to in-
teract with and prevent the aggregation of target proteins. Our previous
work has shown that αB-c is most effective (on a mole: mole basis) at
preventing the aggregation of slowly aggregating target proteins com-
pared to those aggregating more quickly [10,181], presumably because
of the requirement for active subunits to dissociate from larger oligomers
as part of the chaperone action of this sHsp. Thus, when proteinaggregation occurs very fast it may exceed the rate at which active sHsp
subunits can dissociate, therefore leading to a decrease in the chaperone
efﬁcacy of the sHsp.4.1. Expression of sHsps in the brain
Of the ten identiﬁed human sHsps, some are ubiquitously expressed
(e.g. Hsp27 andαB-c), whilst others are found onlywithin speciﬁc tissues
[182,183]. For example, αA-c is only present at appreciable levels within
the eye lens, where, together withαB-c, it formsα-crystallin, the hetero-
oligomeric lens protein which is responsible for maintaining lens trans-
parency via its chaperone action and ordered arrangement [184,185].
Given the important role sHsps have in proteostasis, it is surprising that
there has not been a systematic study of sHsp expression and localisation
in the human brain. In relation to neurodegenerative conditions such as
theα-synucleinopathies, ﬁve sHsps are expressedwithin the central ner-
vous system.Myotonic dystrophy protein kinase binding protein (HSPB2)
is expressed in smooth muscle of vessel walls of the brain [186], and
compartment-speciﬁc expression of Hsp20, Hsp22, Hsp25 (the murine
ortholog of human Hsp27) and αB-c has been demonstrated within
other brain tissues of the mouse [187]. Hsp27 is expressed in motor and
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also constitutively expressed, along with αB-c, in glial cells [186].
Although there is some evidence for the neuroprotective capabilities
of Hsp20 and Hsp22 [182], Hsp27 and αB-c have attracted the most
attention in relation to neurodegenerative disease. Expression of both
αB-c and Hsp27 is highly induced in response to neurological stress
[151,189]. Hsp27 andαB-c are expressed in reactive astrocytes adjacent
to senile plaques in both normal aged brains and in neurodegenerative
conditions, such as Alzheimer's disease [186], and their expression is in-
creased in reactive astrocytes in the hippocampus of PD patients with
dementia [190]. Moreover, Hsp27 is one of the most strongly induced
proteins across several brain regions in PD patients [191] and its levels
are 2.5-fold higher in pathologically conﬁrmed cases of Dementia with
Lewy bodies than age-matched controls. Chen and Brown [23] com-
pared constitutive and inducible Hsp27 expression in several neuronal
subtypes associated with neurodegenerative diseases, including PD
and amyotrophic lateral sclerosis (ALS). Constitutive Hsp27 expression
was found within motor neurons of the spinal cord (the degeneration
ofwhich is associatedwith ALS), but Hsp27was not detectedwithin do-
paminergic neurons of the substantia nigra (the degeneration of which
is associated with PD). Chen and Brown speculated that one reason
ALS is approximately 33 times less frequent than PD is that motor neu-
rons in the spinal cord are better equipped to manage misfolded pro-
teins than dopaminergic neurons due to the protection provided by
the levels of Hsp27 [23]. Thus, the low basal expression of Hsp27 in do-
paminergic neurons [23,154] may facilitate the onset of α-syn aggrega-
tion in these cells. The increased expression of sHsps in the context of
the α-synucleinopathies may be a consequence of the cellular stress
conditions that accompanies the onset and progression of these diseases.
4.2. The effects of small heat-shock proteins on α-synuclein aggregation
The presence of sHspswithin Lewy bodies and their up-regulation in
the surrounding neuronal tissues associated with a number of α-
synucleinopathies have led to an examination of how sHsps interact
with, and inﬂuence the aggregation of, α-syn. These ﬁndings, based on
studies using in vitro α-syn aggregation assays, and cell- and animal-
based models of α-syn aggregation are summarised in Table 1.Table 1
A summary of studies that have investigated interactions between sHsps and α-syn. Key ﬁ
Method used α-Syn Isoform sHsp(s) Key Findings
In vitro aggregationassays and atomic
force microscopy
WT
A53T
A30P
E46K
Hsp27
αB-c
Hsp20
Hsp22
HspB2B3
• sHsps bind α-syn var
• sHsps reduce the am
clustered morphology
In vitro aggregation assays and
transmission electron microscopy
(TEM)
WT
A53T
A30P
αB-c • αB-c inhibits α-syn ﬁ
• The number of ﬁbrils
In vitro aggregation assays WT αB-c • The ability of αB-c to
• αB-c inhibits further
In vitro assay, TEM A53T αB-c • The interaction of αB
and ends of mature α-
• Fibril-bound αB-c inh
In vitro aggregation assays A53T αB-c • αB-c signiﬁcantly red
tissue of transgenic m
Cell-based model WTA53TA30P Hsp27 • Hsp27 expression pro
including serum withd
Cell-based model WT
A53T
Hsp27
αB-c
• Both Hsp27 and αB-c
• Hsp27 reduces inclus
• Hsp27 protects prim
Cell-based model WT Hsp27 • Hsp27 does not coloc
In vivomurine A53T Hsp25⁎
αB-c
• Hsp25 levels are sign
cord tissue of A53T α-
•αB-c levels are increa
In vivo Drosophila WT αB-c • αB-c reduces the ‘rou
in Drosophila.
⁎ Hsp25 is the murine ortholog of human Hsp27.4.2.1. In vitro α-synuclein aggregation assays
sHsps interact with multiple species formed along the α-syn off-
folding aggregation pathway (Fig. 4). Various sHsps, including Hsp27
and αB-c, bind monomeric α-syn in vitro, with a dissociation rate con-
stant (koff) in the range of 10−3 s−1, as determined by surface plasmon
resonance measurements, suggesting a weak, transient interaction that
nonetheless inhibits its aggregation [15]. The ability of dyes such as
thioﬂavin T (ThT) to bind to β-sheet structures (such as those found
in α-syn ﬁbrils) has been used to monitor the aggregation kinetics of
α-syn and provide a quantitative measure of ﬁbril formation. Bruinsma
et al. [15] assessed a panel of sHsps, includingHsp27, Hsp20, Hsp22,αB-
c and hetero-oligomers of HSPB2 and HSPB3, for their ability to inhibit
α-syn aggregation using both in vitro ThT assays and atomic force mi-
croscopy. They reported that Hsp27 is the most efﬁcacious of these
sHsps with regards to preventing ﬁbril formation of WT α-syn and it
does so by inhibiting both the lag and elongation phases of aggregation
[15]. This leads to an overall reduction in the number and size of ﬁbrils.
Comparable effects were observed when Hsp27 was incubated with
E46K and A30P α-syn, however, the presence of Hsp27 increased the
aggregation of A53Tα-syn compared towhenno chaperonewas present
[15].αB-crystallin also inhibits the aggregation ofα-syn (and its disease-
related mutant forms) in vitro and does so at sub-stoichiometric levels
[11]. In addition, the in vitro ﬁbrillar aggregation of A53T α-syn isolated
from brain tissue extracts of transgenic mice is signiﬁcantly reduced by
the presence of αB-c [193]. As with Hsp27, the addition of αB-c not
only increases the lag phase ofα-syn aggregation, slowing the formation
of preﬁbrillar intermediates, but also inhibits the elongation phase, indi-
cating that it acts to stabilise monomeric and preﬁbrillar α-syn species
[11,14]. Notably, the efﬁciency with which αB-c inhibits α-syn ﬁbril for-
mation correlates with the aggregation-propensity of the α-syn isoform
[11,15]. Thus, at a given molar ratio, αB-c is more effective at inhibiting
the aggregation of WT α-syn (which aggregates the slowest) and is less
effective against A53T α-syn (which aggregates the fastest).
Most studies that have tested the in vitro chaperone action of the
sHsps have involved addition of the chaperone toα-syn before aggrega-
tion has commenced, and therefore focussed on the interaction of the
chaperone with species formed in the early stages of aggregation [11,
15,196]. However, in addition to interacting with monomeric andndings regarding this interaction are categorised according to the method used.
Reference
iants in a weak, transient but speciﬁc manner.
ount of ﬁbrillar aggregation resulting in ﬁbrils that are shorter, and have a
.
[15]
bril formation at substoichiometric ratios.
is signiﬁcantly reduced and amorphous-like aggregates are produced.
[11]
suppress α-syn aggregation increases with temperature.
aggregation when introduced during the elongation phase of ﬁbril growth.
[14]
-c with α-syn monomers is weak and transient. αB-c binds along the face
syn ﬁbrils.
ibits further elongation.
[192]
uces the in vitro aggregation of α-syn extracted and puriﬁed from brain
ice.
[193]
tects stably transfected ND7 α-syn-expressing cells from cell death stimuli
rawal.
[194]
co-localise with α-syn inclusions in co-transfected H4 neuroglioma cells.
ion formation, although both αB-c and Hsp27 reduce α-syn toxicity.
ary dopaminergic neurons from α-syn toxicity.
[149]
alise with α-syn in inclusions. [147]
iﬁcantly up-regulated in both the soluble and insoluble fractions of spinal
syn. over-expressing transgenic mice.
sed in the insoluble fraction of spinal cord tissue from these transgenicmice.
[193]
gh eye’ phenotype induced by α-synuclein expression and aggregation [195]
Fig. 4. sHsps interact with various species formed during theﬁbrillar aggregation ofα-syn.Unfoldedα-syn aggregates through a nucleation-dependentmechanism, and the resultant
ﬁbrillar deposits may then be sequestered into inclusion bodies. Fragmentation of mature ﬁbrils can generate additional oligomeric nuclei, further perpetuating aggregation. (1) The in-
teraction of sHsps with monomeric aggregation-prone α-syn. The mechanism of this interaction remains to be fully elucidated but may involve one or more of (i) weak transient in-
teractionswithα-synwhich prevent it from associating into oligomeric nuclei, (ii) the formation of a stable complex betweenα-syn and the sHspswhich,when cellular conditions permit,
enablemonomericα-syn to be released, or (iii)α-syn being induced to form amorphous aggregates rather than ﬁbrils. (2) The interaction of sHsps with preﬁbrillar intermediates and
mature α-syn ﬁbrils. sHsps can bind to oligomeric and ﬁbrillar forms of α-syn with moderate (μM) afﬁnity. In doing so, they inhibit further ﬁbril growth andmay lead to tangling of the
ﬁbrils into larger ‘inclusion-like’ deposits. Solid lines represent pathways that are well supported by the current literature, dotted lines represent proposed pathways in which the details
are yet to be fully resolved.
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bind to species formed further along the aggregation pathway including
mature ﬁbrils [14,192]. Thus, when introduced during the elongation
phase of α-syn aggregation, αB-c prevents further ﬁbril growth by
binding along the length of mature ﬁbrils [14,192]. Recent work, using
apolipoprotein C-II (apoC-II) as a model ﬁbril-forming protein has
shown that, by binding to ﬁbrils, αB-c stabilises them and prevents
their dilution-induced fragmentation [12]. Moreover, binding of αB-c
to apoC-II ﬁbrils also causes them to associate (tangle) into larger
species reminiscent of protein inclusions [12]. Thus, it appears that by
binding toﬁbrils, sHsps inhibit their fragmentation and prevent second-
ary nucleation events, both of which contribute to ﬁbril toxicity [197].
Moreover, whilst the presence of sHspswithin inclusions had been con-
sidered a by-product of their failed attempt to mitigate aggregation
[196], their ability to stabilise mature α-syn ﬁbrils provides another
rationale for their localisation in these deposits. Finally, recently αB-c
was shown to also promote the dissociation of potentially toxic
β2-microglobulin oligomers into monomers, highlighting another
role these chaperones may have in cells to protect them from α-syn
oligomer-induced toxicity [198].
In summary, the interaction of sHspswith aggregation-proneα-syn is
multi-faceted; it involves binding to monomeric, oligomeric, preﬁbrillar
and ﬁbrillar forms of the protein in order to prevent the toxicity associat-
ed with the aggregation process. However, as the chaperone action of
sHsps is dependent on the supply of dissociated (chaperone-active) spe-
cies from larger oligomers, the dynamic relationship between the rate at
whichα-syn aggregates and the rate of sHsp subunit exchange therefore
appears to be an important factor with regards to whether or not sHsps
can prevent α-syn deposition in the context of the α-synucleinopathies.
4.2.2. Cell-based models of α-synuclein aggregation
Whilst it is clear that sHsps can interact with α-syn to inhibit its
aggregation in vitro, it remains to be conclusively established whether
this occurs in the cellular environment. Most cell-based models of
α-syn aggregation and associated toxicity are based on the exogenousapplication of aggregated α-syn to cells in culture. The susceptibility
of dopaminergic neurons to exogenous α-syn ﬁbrils was illustrated
using preaggregated fragments ofα-syn derived from a ﬁbrillogenic re-
gion of the protein encompassing residues 61-95 [199]. Administration
of these ﬁbrillarα-syn peptides to rat primarymesenchephalic neurons
results in a reduction of dopaminergic neurons and dopamine content
[199].Whilst exogenous application ofα-synﬁbrilsmay have relevance
to cell-to-cell propagation of aggregated α-syn [200–203], the intracel-
lular aggregation of α-syn into Lewy body-like deposits most likely re-
capitulates the earliest events in disease and therefore is considered the
most relevant with regard to α-syn's interaction with sHsps.
Overexpression of α-syn (via transfection or viral induction) has
been examined in both primary and immortalised cell lines. Overex-
pression of bothWT and A53Tα-syn in primarymesenchephalic neuro-
nal cultures not only results in signiﬁcant cell death, which is speciﬁc to
dopaminergic neurons and does not impact the viability of the other
cells in the culture, but also renders surviving dopaminergic neurons
more susceptible to neurotoxic insults [204,205]. Overexpression of
WT, A53T and A30P α-syn in human neuroblastoma cells (SH-SY5Y)
is not sufﬁcient to cause extensive inclusion formation. However, co-
treatment with various agents that induce generation of ROS (e.g. rote-
none, papaNONOate and FeCl2) results in the formation of cytoplasmic
protein inclusions in cells [206,207]. The inclusions contain both α-syn
and ubiquitin and are therefore typical of Lewy bodies isolated
from diseased tissue [206,207]. Thus, it appears that the presence
of aggregation prone forms of α-syn per se is not sufﬁcient to disrupt
cellular proteostasis, however, a second insult that impacts on the
proteostasis network can induce the formation of these protein
inclusions.
In studies in which α-syn is over-expressed, the extent of α-syn
aggregation is dependent on both the level and isoform of α-syn
expressed: A53T α-syn had an increased tendency to form inclusions,
consistent with its increased propensity to form ﬁbrils in vitro and its ge-
netic associationwith early onset PD [206].McLean et al. [208] expressed
an α-syn isoform which was C-terminally tagged with enhanced green
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that overexpression of this protein results in cytoplasmic inclusions in
~5% of transfected cells. Interestingly, cotransfection with synphilin-1,
a protein which binds α-syn in vivo, increased the percentage of cells
containing inclusions to ~55% [208,209]. Notably, although the α-syn
was expressedwith an EGFP ﬂuorescent tag, inclusionswere not ﬂuores-
cent or reactive to anti-EGFP antibodies [208]. Thiswas due to C-terminal
truncation of the EGFP attached toα-syn in these cells, generating a non-
ﬂuorescent form of the protein which aggregated to form inclusions.
Thus, these ﬁndings highlight the potential problems with tagging α-
syn (and indeed other proteins) tomonitor its aggregation in cells. Alter-
native methods for studying full-length α-syn aggregation in cells have
also been developed. For example, using a tetra-cysteine tagged α-syn,
which was either microinjected or transfected into cells and detected
by labelling with a ﬂuorogenic biarsenical compound, Bertoncinni et al.
[210] demonstrated that the aggregation of α-syn into inclusions is sig-
niﬁcantly increased (by up to 10%) by co-treating the cells with FeCl2
to induce oxidative stress. More recently, α-syn aggregation in cells
was modelled by the addition of a 16 amino acid peptide (termed CL1)
to the C-terminus of α-syn, and this was used to demonstrate a correla-
tion between increasing numbers of α-syn aggregates in cells and a re-
duction in cell viability [211].
Much of what is known about the interaction between sHsps and
α-syn in cells comes from cell-based models of α-syn like those de-
scribed above. However, in general these cell models have only been
used qualitatively to assess the effects of sHsps on α-syn aggregation.
One issue with these cell culture models of α-syn aggregation (which
has hampered their use in quantitative studies) is that often only a
small proportion of the cells in culture develop inclusions when
transfected [208]. This severely limits the types of biochemical analyses
that can be undertaken with these models. Despite this, there is some
evidence for sHsps inhibiting α-syn aggregation in cells. For example,
using an α-syn overexpression system coupled with viral-mediated
Hsp expression in ND7 cells, Zourlidou et al. [194] reported a reduction
in α-syn-induced cellular toxicity following overexpression of Hsp27.
Although this study focused on the inherent susceptibility of α-syn-
expressing cells to external cell death stimuli, such as serum removal,
without directly considering α-syn aggregation, it was concluded that
Hsp27 is neuroprotective. Outeiro et al. [149] used overexpression of
the truncated EGFP-tagged WT α-syn in H4 cells (a model discussed
above) to examine the effect of sHsps on α-syn aggregate formation
and reported that cotransfection with Hsp27 signiﬁcantly reduced the
percentage of cells containing α-syn inclusions. Both Hsp27 and αB-c
reduced the inherent toxicity of α-syn expression to levels similar to
those seen when Hsp70 is expressed in these cells [149]. The same ef-
fect was reproduced when A53T α-syn was overexpressed in primary
midbrain cultures [149,212]. Furthermore, a reduction in the endoge-
nous levels of Hsp27 by siRNA resulted in a concentration-dependent
increase in α-syn toxicity in the transfected H4 model [149].
Apart from their ability to inhibit aggregation, sHsps may protect
cells from the toxicity associated with α-syn aggregation in other ways.
Both Hsp27 and αB-c increase the resistance of cells to oxidative stress
[213–215] and can inhibit apoptosis via a range of interactions with part-
ner proteins involved in cell death pathways [216]. For instance, αB-c
inhibits autocatalytic maturation of caspase-3 [217], and Hsp27 binds
to caspase-3 and cytochrome-c released frommitochondria causing in-
activation of the caspase cascade [218,219]. Caspase-independent
mechanisms have also been described, inwhichHsp27 inhibits the abil-
ity of Daxx (death domain-associated protein 6) to interact with Ask1
(apoptosis signal-regulated kinase 1) and Fas (a cell death regulator)
[220], whilst αB-c interacts with Bax and Bcl-2 to inhibit their translo-
cation to the mitochondria [221]. These interactions have all been
shown to provide sHsp-mediated protection from apoptosis in cells.
Thus, sHsps may protect cells from the cytotoxic effects of α-syn aggre-
gation via multiple mechanisms, not just by affecting its aggregation
state. Together, these cell culture studies have provided promisingglimpses of the role (and therapeutic potential) of sHsps in preventing
toxicity associated with α-syn aggregation in cells. However, more ro-
bust and reliable cell culture models of α-syn aggregation are required
so that the precise impact of sHsps on α-syn aggregation and its associ-
ated toxicity can be unequivocally determined.
4.2.3. Animal-based models of α-synuclein aggregation
Surprisingly little work has been conducted into the impact of sHsps
on α-syn aggregation and its associated toxicity using animal models.
Various transgenic mouse models have been developed to study the
α-synucleinopathies (extensive reviews of this work are found in
[222–224]). An example of one such model is that developed by Lee
and colleagues [225], inwhich the transgene is introduced via embryon-
ic pronuclear injection resulting in overexpression of human α-syn in
glia and the neurons of the substantia nigra pars compacta. This model
is characterised by pathological accumulation of α-syn in neuro-
nal cell bodies and neurites in regions of the brain and spinal
cord, in parallel with ubiquitin deposition, reminiscent of the pro-
teinaceous inclusions characteristic of the α-synucleinopathies
[225]. Using this model, immunohistochemical analysis of tissues
from symptomatic transgenic A53T α-syn mice demonstrated that
the expression of αB-c and Hsp25 increases in reactive astroglia and oli-
godendrocytes within affected regions of the central nervous system
[193].
Transgenicα-synmodels have also been developed in rats,Drosophila
melanogaster and Caenorhabditis elegans, as well as alternative models in
which preaggregated α-syn protein or fragments are injected directly
into the substantia nigra [195,199,226–231]. These models have
been used as experimental tools to study the toxicity associated
with α-synuclein aggregation. However, the impact sHsps have on
α-syn aggregation in these models is yet to be explored. Tue et al. [195]
did demonstrate a reduction in the rough-eye phenotype of α-syn trans-
genic Drosophila in the presence ofαB-c, however the inhibition ofα-syn
aggregation was not directly examined. Disease-relevant models such as
these provide valuable tools to further examine the role (and therapeutic
potential) of sHsps in preventing α-syn aggregation in vivo and also may
shed further light on the manner by which the cellular defences against
protein aggregation are overwhelmed in the α-synucleinopathies.
5. Conclusions
The aggregation of α-syn into protein inclusions (Lewy bodies
and Lewy neuritis) underlies the onset and progression of the α-
synucleinopathies and represents a failure of the proteostasis network
in maintaining the protein in a biologically active, non-toxic form. Key
components of the proteostasis network are molecular chaperones
and of these the sHsps are the cell's ﬁrst line of defence against protein
aggregation.We need to better understandwhy sHsps fail to preventα-
syn aggregation in the context of the α-synucleinopathies. One of the
main factors appears to be that the relatively low basal levels of αB-c
and Hsp27 in dopaminergic neurons of the substantia nigra makes
them more susceptible to protein aggregation. If this is the case, then
boosting their expression may be a target for therapeutic intervention.
Whilst it has been generally considered that the role of sHsps in the
chaperone network is to stabilise partially folded intermediate states of
proteins to prevent their aggregation, recent work has demonstrated
that their mechanism of action is much more multi-faceted. In relation
to α-syn aggregation, sHsps interact with multiple species formed dur-
ing the aggregation process, from monomeric partially folded interme-
diate states through to the mature ﬁbrils themselves. The biological
relevance of these interactions must now be further examined using
more sophisticated disease-relevant cell and animal models of the
α-synucleinopathies.
In addition, whilst many studies have primarily considered the abil-
ity of the sHsps to inhibit or preventα-syn aggregation in vitro, the lim-
ited number of cellular and in vivo studies performed to date indicates
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cells. Instead, sHsps may afford protection against the toxicity associat-
ed withα-syn aggregation via their impacts on other cellular pathways,
such as by inhibiting ROS formation or apoptosis. The common theme in
all this work is that sHsps act, through their chaperone activity, to stabi-
lise proteins and prevent their improper interactions in cells. In doing
so, they maintain cell viability and therefore are key components of
the proteostasis network. In the α-synucleinopathies, targeting their
chaperone activity may open up new therapeutic avenues to treat
these currently intractable and debilitating diseases.Acknowledgments
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